| Risk factors for bleeding and clinical implications in patients undergoing liver transplantation ME Gamil, J Pirenne, H Van Malenstein, M Verhaegen, B Desschans, ... Transplantation proceedings 44 (9), 2857-2860, 2012 | 64 | 2012 |
| Simeprevir plus sofosbuvir for eight or 12 weeks in treatment‐naïve and treatment‐experienced hepatitis C virus genotype 4 patients with or without cirrhosis M El Raziky, M Gamil, MK Ashour, EA Sameea, W Doss, Y Hamada, ... Journal of viral hepatitis 24 (2), 102-110, 2017 | 37 | 2017 |
| The future for the treatment of genotype 4 chronic hepatitis C G Esmat, M El Raziky, M El Kassas, M Hassany, ME Gamil Liver International 32, 146-150, 2012 | 37 | 2012 |
| Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues G Esmat, M El Kassas, M Hassany, M Gamil, M El Raziky Liver International 34, 24-28, 2014 | 36 | 2014 |
| Novel scores combining AFP with non‐invasive markers for prediction of liver fibrosis in chronic hepatitis C patients M Gamil, M Alboraie, M El‐Sayed, A Elsharkawy, N Asem, T Elbaz, ... Journal of medical virology 90 (6), 1080-1086, 2018 | 26 | 2018 |
| How to optimize HCV therapy in genotype 4 patients G Esmat, M El Kassas, M Hassany, ME Gamil, M El Raziky Liver International 33, 41-45, 2013 | 26 | 2013 |
| Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection MS Sulkowski, JJ Feld, E Lawitz, F Felizarta, AM Corregidor, O Khalid, ... Journal of viral hepatitis 25 (6), 631-639, 2018 | 16 | 2018 |
| Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: preliminary results from a phase IIa, partially randomised, open-label trial conducted in Egypt … M El Raziky, M Gamil, R Hammad, MS Hashem, M Khairy, A Elsharkawy, ... Hepatology 62, 784A-784A, 2015 | 16 | 2015 |
| Should chronic hepatitis B be treated as early as possible? F Hulstaert, C Schwierz, F Nevens, N Thiry, M Gamil, I Colle, ... International journal of technology assessment in health care 29 (1), 35-41, 2013 | 12 | 2013 |
| A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. ÖM Koc, J Verbeek, GH Koek, R Bielen, D Busschots, M Gamil, ... Acta Gastro-enterologica Belgica 85 (1), 56-61, 2022 | 6 | 2022 |
| Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study E Lawitz, F Poordad, JA Gutierrez, M Beumont, G Beets, A Vandevoorde, ... Health Science Reports 3 (2), e145, 2020 | 6 | 2020 |
| Treatment of chronic HCV genotype 4 infection G Esmat, M El Raziky, M El-Kassas, M Hassany, ME Gamil Current Hepatitis Reports 11 (4), 250-255, 2012 | 6 | 2012 |
| Treatment of hepatitis C genotype 4 patients with simeprevir and sofosbuvir: results from a phase IIa, partially randomized, open-label trial conducted in Egypt (OSIRIS) M El Raziky, M Gamil, R Hammad, M Hashem Annual Meeting of the American Association for the Study of Liver Diseases …, 2015 | 5 | 2015 |
| Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection with or without Cirrhosis Treated with Interferon-Free, Simeprevir-Containing Regimens: Results … E Chan, E Lawitz, PY Kwo, MS Sulkowski, M Gamil, C Corbett, D Luo, ... Gastroenterology 152 (5), S1094-S1095, 2017 | 2 | 2017 |
| PHARMACOKINETIC INTERACTION BETWEEN THE P-GLYCOPROTEIN SUBSTRATE DABIGATRAN ETEXILATE AND HCV DIRECT-ACTING ANTIVIRAL AGENTS, ODALASVIR AND SIMEPREVIR. S Ouwerkerk-Mahadevan, M Gamil, S Van Hemelryck, V Hillewaert, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S84-S84, 2018 | 1 | 2018 |
| A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS SA MacParland, V Cherepanov, L Vijgen, M Gamil, M Beumont, S Yoon, ... Journal of the Canadian Association of Gastroenterology 1 (suppl_1), 284-285, 2018 | 1 | 2018 |
| Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naive patients SA MacParland, V Cherepanov, L Vijgen, M Gamil, M Beumont, S Yoon, ... HEPATOLOGY 63 (1 SUPP), 732A-732A, 2016 | 1 | 2016 |
| Psychometric Evaluation of the Pediatric RSV Severity and Outcomes Rating System Version 7 (PRESORSv7. 1, Observer-Reported and PRESORSv7 Clinician-Reported Forms) Scores in … S Qin, L Nelson, L McLeod, J Ma, BL Sanchez, M Gamil, M Stevens, ... QUALITY OF LIFE RESEARCH 30 (SUPPL 1), S16-S17, 2021 | | 2021 |
| Long-term outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: an observational cohort study ÖM Koc, G Robaeys, H Topal, R Bielen, D Buscchots, ME Gamil, J Fevery, ... Journal of Hepatology 70, E260-E260, 2019 | | 2019 |
| Deep Sequencing Results from the Phase 2 Impact Study of Simeprevir in Combination with Daclatasvir and Sofosbuvir in Treatment-Naïve and-Experienced Patients with Chronic … C Sarrazin, V Van Eygen, L Vijgen, M Gamil, M Beumont, E Lawitz, ... Journal of Hepatology 2 (64), S399, 2016 | | 2016 |
